Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-23
2005-08-23
Chernyshev, Olga N. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S184100, C424S185100, C424S198100, C530S350000, C530S399000
Reexamination Certificate
active
06933277
ABSTRACT:
This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.
REFERENCES:
patent: 5767240 (1998-06-01), Brenneman et al.
patent: WO 92/18140 (1992-10-01), None
patent: WO 96/11948 (1996-04-01), None
patent: WO 98/35042 (1998-08-01), None
Hannigan et al., Neurotoxicol. & Teratol., 22(1):103-11, 2000.
Skolnick et al., Trends in Biotech. 18(1):34-39, 2000.
Smith AE., Ann. Rev. of Microbiol., 49:807-38, 1995.
Mahato et al., J. of Drug Targeting, 4(6):337-57, 1997.
Spong et al., Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.J Pharmacol Exp Ther.;297(2):774-9 (2001).
Wilkemeyer et al., Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicityPNAS100: 8543-8548 (2003).
Spong et al., “Prevention of Fetal Alcohol Syndrome by Novel Peptides”,FASEB JOURNAL, 13:(5) part 2, p. A881 XP-002148904, (Mar. 15, 1999).
Spinney L., “New Peptides prevent brain damage 'news!”,Molecular Medicine Today5:(7)282 (Jul. 1999).
Oberdoester, J. et al., “The Effects of ethanol on neuronal cell death: Implication for the fetal alcohol syndrome”,FASEB Journal, 12:4 A134 (Mar. 17, 1998).
Bassan, M. et al. “VIP-Induced Mechanism of Neuroprotection: The Complete Sequence of a Femtomolar-Acting Activity-Dependent Neuroprotective Protein.”Regulatory Peptides, 71(2):, Aug. 15, 1997.
Bassan, M. et al. “Complete Sequence of a Novel ProteinContaining a Femtomolar-Activity-Dependent Neuroprotective Peptide.”Journal of Neurochemistry72:1283-1293 (1999).
Beni-Adani, L. et al. “Activity-Dependent Neurotrophic Protein is Neuroprotective in a Mouse Model of Closed Head Injury.” Society for Neuroscience, 28thAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts23(1):1043 (1998).
Brenneman, D.C. and Gozes, I. “A Femtomolar-Acting Neuroprotective Peptide.”Journal of Clinical Investigation97:229-230 (1996).
Brenneman, D.E. et al. “Identification of a Nine Amino Acid Core Peptide from Activity Dependent Neurotrophic Factor I.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2): 2250 (1997).
Brenneman, D.E. et al. “Activity-Dependent neutotrophic Factor: Structure-Activity Relationships of Femtomolar-Acting Peptides.”Journal of Pharmacology and Experimental Therapeutics285: 619-627 (1998).
Davidson, A. et al. “Protection Against Developmental Retardation and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2)2250 (1997).
Dibbern, D.A., Jr. et al. “Inhibition of Murine Embryonic Growth by Human Immunodeficiency Virus Envelope Protein and Its Prevention by Vasoactive Intestinal Peptide and Activity-Dependent Neurotrophic Factor.”Journal of Clinical Investigation99: 2837-2841 (1997).
Giladi, E. “Protection Against Developmental and Learning Impairments in Apolipoprotein E-Deficient Mice by Activity-Dependent Femtomolar-Acting Peptides.”Neuroscience LettersSupplement 48 S1-S60, P. S19 (1997).
Glazner, G.W. et al. “A 9 Amino Acid Peptide Fragment of Activity-Dependent Neurotrophic Factor (ADNF) Protects Neurons from Oxidative Stress-Induced Death.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2)2249 (1997).
Gozes, I. et al. “Stearyl-Norleucine-Vasoactive intestinal Peptide (VIP): A novel VIP Analog for Noninvasive Impotence Treatment.”Endocrinology134: 2125 (1994).
Gozes, I. et al. “Superactive Lipophilic Peptides Discriminate Multiple Vasoactive intestinal Peptide Receptors.”Journal of Pharmacology and Experimental Therapeutics27:3161-167 (1995).
Gozes, I. et al. “Neuroprotective Strategy for Alzheimer Disease: Intranasal Administration of a Fatty Neuropeptide.”Proc. Natl. Acad. Sci. USA93:427-432 (1996).
Gozes, I. and Brenneman, D.E. “Activity-Dependent Neurotrophic Factor (ADNF).”Journal of Molecular Neuroscience7:235-244 (1996).
Gozes, I. et al. “Protection Against Developmental Retardation in Apolipoprotein E-Deficient Mice by a Fatty neuropeptide: Implications for Early Treatment of Alzheimer's Disease.”Journal of Neurobiology33:329-342 (1997).
Gozes I. et al. “Antiserum to Activity-Dependent Neurotrophic Factor Produces Neuronal Cell Death in CNS Cultures: Immunological and Biological Specificity.”Developmental Brain Research99:167-175 (1997).
Gozes, I. et al. “The cDNA Structure of a Novel Femtomolar-Acting Neuroprotective Protein: Activity-Dependent-Neurotrophic Factor III (ADNFIII).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2):2250 (1997).
Gozes, I. et al. A Femtomolar-Acting Activity-Dependent Neuroprotective Protein (ADNP).Neuroscience LettersSupplement 48 S1-S60, p. S21 (1997).
Hill, J.M. et al. “Learning Impairment in Adult Mice Produced by Early Embryonic Administration of Antiseum to Activity-Dependent Neurotrophic Factor (ADNF).” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2):2250 (1997).
Lilling, G. et al. “Inhibition of Human Neuroblastoma Growth by a Specific VIP Antagonist.”Journal of Molecular Neuroscience5: 231-239 (1995).
McKune, S.K. et al. “Localization of mRNA for Activity-Dependent Neurotrophic Factor III (ADNF III) in mouse Embryo and Adult CNS.” Society for Neuroscience, 27thAnnual Meeting, New Orleans, LA, Oct. 25-30, 1997.Abstracts23(2):2249 (1997).
Nelbock, P. et al. A cDNA for a Protein that Interacts with the Human Immunodeficiency Virus Tat Transactivator.Science, 248:1650-1653 (1990).
Pelsman, A. et al. “In Vitro Degeneration of Down Syndrome neurons is Prevented by Activity-Dependent Neurotrophic Factor-Derived Peptides.” Society for Neuroscience, 28THAnnual Meeting, Los Angeles, CA, Nov. 7-12, 1998.Abstracts24:1044 (1998).
Brenneman et al. “Neuronal Cell Killing by the Envelope Protein of HIV and Its Prevention by Vasoactive Intestinal Peptide.”Nature335:636 (1988).
Brenneman et al. “N-Methyl-D-Aspartate Receptors Influence Neuronal Survival in Developing Spinal Cord Cultures”Dev. Brain Res. 51:63 (1990).
Glazner, G.W. et al. “Activity Dependent Neurotrophic Factor: A Potent Regulator of Embryonic Growth.”Anat. Embryol. 200:65-71 (1999).
Gressens, P. et al. “Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos.”Nature, 362:155-58 (1993).
Bassan Merav
Brenneman Douglas E.
Gozes Illana
Spong Catherine Y.
Zamostiano Rachel
Chernyshev Olga N.
Ramot University Authority for Applied Research and Industrial D
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Prevention of fetal alcohol syndrome and neuronal cell death... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of fetal alcohol syndrome and neuronal cell death..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of fetal alcohol syndrome and neuronal cell death... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3476751